Population Pharmacokinetic and Exposure–Response Analyses for Ponatinib in the Phase 3 PhALLCON Study
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70175 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Michael J Hanley und 8 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Imidazoles, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Pyridazines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
In March 2024, ponatinib received accelerated FDA approval for the treatment of newly diagnosed Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph + ALL) in combination with chemotherapy based on the Phase 3 PhALLCON study (NCT03589326), which demonstrated a higher rate of minimal residual disease (MRD)‐negative complete remission (CR) at the end of induction (EOI) with ponatinib (34.4%) versus imatinib (16.7%; p = 0.002). Patients received ponatinib (30 mg QD with reduction to 15 mg QD upon achievement of MRD‐negative CR at EOI) or imatinib (600 mg QD) combined with 20 cycles of reduced‐intensity chemotherapy (induction: 3 cycles; consolidation: 6 cycles; and maintenance: 11 cycles). Ponatinib pharmacokinetics (PK) were similar in patients in PhALLCON and patients in a previous population PK analysis. Bayesian re‐estimation of the previously developed population PK model adequately described PhALLCON PK data. Exposure–efficacy analyses did not identify a significant relationship between ponatinib exposure and the probability of MRD‐negative CR at EOI ( p = 0.619), suggesting a consistent efficacy benefit across exposures. Ponatinib exposure was not a significant predictor of arterial occlusive events, venous thromboembolic events, thrombocytopenia, or lipase increase ( p > 0.05). However, higher exposures were associated with a higher probability of hypertension ( p = 0.0340) and alanine aminotransferase (ALT) increase ( p = 0.0034). Dose reduction from 30 to 15 mg was predicted to decrease the odds of experiencing hypertension by 37.7% and ALT increase by 44.2%. Collectively, exposure–response analyses support a favorable benefit–risk profile of the approved ponatinib dosage (30 mg QD reduced to 15 mg QD upon achievement of MRD‐negative CR at EOI), combined with chemotherapy, for frontline treatment of Ph + ALL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
- Certara, Radnor, Pennsylvania, USA.
ORCID-Profile: Michael J Hanley, Thomas R Larson, Paul M Diderichsen, Anna Largajolli, Neeraj Gupta
Zitieren
APA
Hanley, M. J., Larson, T. R., Diderichsen, P. M., Largajolli, A., Hui, K., Srimani, J., Wang, B., Vorog, A., & Gupta, N. (2025). Population Pharmacokinetic and Exposure–Response Analyses for Ponatinib in the Phase 3 PhALLCON Study. Clinical and Translational Science. https://doi.org/10.1111/cts.70175
Vancouver
Hanley MJ, Larson TR, Diderichsen PM, Largajolli A, Hui K, Srimani J, et al. Population Pharmacokinetic and Exposure–Response Analyses for Ponatinib in the Phase 3 PhALLCON Study. Clinical and Translational Science. 2025. doi:10.1111/cts.70175
BibTeX
@article{Hanley2025,
author = {Hanley, Michael J and Larson, Thomas R and Diderichsen, Paul M and Largajolli, Anna and Hui, Katrina and Srimani, Jaydeep and Wang, Bingxia and Vorog, Alexander and Gupta, Neeraj},
title = {Population Pharmacokinetic and Exposure–Response Analyses for Ponatinib in the Phase 3 PhALLCON Study},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70175}
}
EUVIMED